Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr;32(13):e1901633.
doi: 10.1002/adma.201901633. Epub 2019 Jun 28.

Materials for Immunotherapy

Affiliations
Review

Materials for Immunotherapy

C Wyatt Shields 4th et al. Adv Mater. 2020 Apr.

Abstract

Breakthroughs in materials engineering have accelerated the progress of immunotherapy in preclinical studies. The interplay of chemistry and materials has resulted in improved loading, targeting, and release of immunomodulatory agents. An overview of the materials that are used to enable or improve the success of immunotherapies in preclinical studies is presented, from immunosuppressive to proinflammatory strategies, with particular emphasis on technologies poised for clinical translation. The materials are organized based on their characteristic length scale, whereby the enabling feature of each technology is organized by the structure of that material. For example, the mechanisms by which i) nanoscale materials can improve targeting and infiltration of immunomodulatory payloads into tissues and cells, ii) microscale materials can facilitate cell-mediated transport and serve as artificial antigen-presenting cells, and iii) macroscale materials can form the basis of artificial microenvironments to promote cell infiltration and reprogramming are discussed. As a step toward establishing a set of design rules for future immunotherapies, materials that intrinsically activate or suppress the immune system are reviewed. Finally, a brief outlook on the trajectory of these systems and how they may be improved to address unsolved challenges in cancer, infectious diseases, and autoimmunity is presented.

Keywords: controlled release; drug delivery; immunotherapy; materials engineering; personalized medicine.

PubMed Disclaimer

Similar articles

Cited by

References

    1. a) L. Milling, Y. Zhang, D. J. Irvine, Adv. Drug Delivery Rev. 2017, 114, 79;
    1. b) M. L. Bookstaver, S. J. Tsai, J. S. Bromberg, C. M. Jewell, Trends Immunol. 2018, 39, 135;
    1. c) R. S. Riley, C. H. June, R. Langer, M. J. Mitchell, Nat. Rev. Drug Discovery 2019.
    1. J. O’Donnell-Tormey, Timeline of Progress in Immunotherapy- Cancer Research Institute, https://www.cancerresearch.org/immunotherapy/timeline-of-progress, (accessed: June 2019).
    1. a) A. S. Timin, M. M. Litvak, D. A. Gorin, E. N. Atochina-Vasserman, D. N. Atochin, G. B. Sukhorukov, Adv. Healthcare Mater. 2018, 7, 1700818;

LinkOut - more resources